
|Slideshows|June 25, 2018
Refined Prediction of MACE in Subclinical Atherosclerosis
Author(s)Veronica Hackenthal, MD
New study finds that noninvasive assessment of CAD with CCTA may help reclassify risk and predict MACE in asymptomatic atherosclerosis.
Advertisement
Source: Guaricci AI, Lorenzoni V, Guglielmo M, et al. Prognostic relevance of subclinical coronary and carotid atherosclerosis in a diabetic and nondiabetic asymptomatic population. Clin Cardiol. 2018;41:769-777.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Sanofi Announces Discontinuation of Amlitelimab for Atopic Dermatitis
2
FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD
3
Dupilumab, Depemokimab, and COPD: What APPs See in Practice
4
Why Does IgA Nephropathy Affect More Men? With Ramy Hanna, MD
5











































































